GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Gross Margin %

Seer (SEER) Gross Margin % : 41.70% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Seer Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Seer's Gross Profit for the three months ended in Dec. 2023 was $1.74 Mil. Seer's Revenue for the three months ended in Dec. 2023 was $4.18 Mil. Therefore, Seer's Gross Margin % for the quarter that ended in Dec. 2023 was 41.70%.


The historical rank and industry rank for Seer's Gross Margin % or its related term are showing as below:

SEER' s Gross Margin % Range Over the Past 10 Years
Min: 42.8   Med: 46.29   Max: 49.87
Current: 46.29


During the past 6 years, the highest Gross Margin % of Seer was 49.87%. The lowest was 42.80%. And the median was 46.29%.

SEER's Gross Margin % is ranked worse than
64.37% of 741 companies
in the Biotechnology industry
Industry Median: 59.43 vs SEER: 46.29

Seer had a gross margin of 41.70% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Seer was 0.00% per year.


Seer Gross Margin % Historical Data

The historical data trend for Seer's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer Gross Margin % Chart

Seer Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial - - 49.87 42.80 46.29

Seer Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.17 46.61 50.23 47.40 41.70

Competitive Comparison of Seer's Gross Margin %

For the Biotechnology subindustry, Seer's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seer's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Seer's Gross Margin % falls into.



Seer Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Seer's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=7 / 15.182
=(Revenue - Cost of Goods Sold) / Revenue
=(15.182 - 8.155) / 15.182
=46.29 %

Seer's Gross Margin for the quarter that ended in Dec. 2023 is calculated as


Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=1.7 / 4.18
=(Revenue - Cost of Goods Sold) / Revenue
=(4.18 - 2.437) / 4.18
=41.70 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Seer  (NAS:SEER) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Seer had a gross margin of 41.70% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Seer Gross Margin % Related Terms

Thank you for viewing the detailed overview of Seer's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Seer (SEER) Business Description

Traded in Other Exchanges
N/A
Address
3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.
Executives
Elona Esq. Kogan officer: General Counsel and Secretary C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad director, 10 percent owner, officer: CEO and Chair of the Board C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas officer: Chief Commercial Officer C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn officer: Chief Financial Officer 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan director, officer: President & COO C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani director C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz director C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer director C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005